BIOMATCELL Stage 4
| Reference number | |
| Coordinator | Göteborgs Universitet - Institutionen för klinisk vetenskaper, Avdelningen för biomaterialvetenskap |
| Funding from Vinnova | SEK 14 000 000 |
| Project duration | June 2015 - May 2017 |
| Status | Completed |
Purpose and goal
Development of platforms for determining the biological effects of 3D manufactured metal and ceramic implants in the orthopaedic and cranio-maxillo-facial fields (Arcam, Oss-DSign, GU, UU, KS, clinical). Development of platform for studying the tissue barriers and properties of bacteria interacting with materials intended for oro-maxillo-facial and orthopaedic applications (Neoss, Integrum, GU, clinical). The analysis of bone and soft tissue integration of novel ideas of bone anchored hearing aids and membranes for Guided bone regeneration (Oticon Medical, Neoss, GU).
Expected results and effects
The mechanisms of tissue integration of titanium alloy, cobalt chrome and ceramic implants prepared using 3D manufacturing techniques were unraveled (Arcam, OssDSign, GU, UU, KS, clinical). A microbiological test platform has been developed, enabling the analysis of bacteria from implants and prostheses with respect to their biofilm forming ability and antibiotic susceptibility (Neoss, Integrum, GU, clinical). New surface modifications and dual barrier concepts, respectively, have been verified in pre-clinical studies (Oticon Medical, Neoss, GU, clinical).
Planned approach and implementation
Phase 4 has addressed unmet clinical needs (tissue integration and biomaterial-associated infection) in two medical fields (cranial/ENT/oro-maxillofacial and orthopaedics) by forming projects with microbiological, molecular, clinical, materials and industrial expertise and critical mass. New technical and microbiological platforms were judged as essential in order to provide deepened insight to material-biology relationships. The results have been extremely valuable for the interpretation of the mechanisms whereby the medical products exert their function.